At the time of writing, Avadel Pharmaceuticals plc [AVDL] stock is trading at $16.13, down -1.22%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The AVDL shares have lost -1.16% over the last week, with a monthly amount glided 9.13%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Avadel Pharmaceuticals plc [NASDAQ: AVDL] stock has seen the most recent analyst activity on June 12, 2024, when Rodman & Renshaw initiated its Buy rating and assigned the stock a price target of $27. Previously, Oppenheimer reaffirmed its Outperform rating on March 05, 2024, and elevated its price target to $29. On March 05, 2024, Needham reiterated its Buy rating and revised its price target to $22 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $25 on March 05, 2024. UBS initiated its recommendation with a Buy and recommended $21 as its price target on February 06, 2024. Jefferies upgraded its rating to Buy for this stock on November 30, 2022, and upped its price target to $11. In a note dated August 10, 2022, Jefferies downgraded an Hold rating on this stock and boosted its target price from $6 to $8.
For the past year, the stock price of Avadel Pharmaceuticals plc fluctuated between $9.50 and $19.09. Currently, Wall Street analysts expect the stock to reach $14.75 within the next 12 months. Avadel Pharmaceuticals plc [NASDAQ: AVDL] shares were valued at $16.13 at the most recent close of the market. An investor can expect a potential drop of -8.56% based on the average AVDL price forecast.
Analyzing the AVDL fundamentals
Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -2.46%, Pretax Profit Margin comes in at -2.84%, and Net Profit Margin reading is -2.84%. To continue investigating profitability, this company’s Return on Assets is posted at -0.93, Equity is -1.5 and Total Capital is -1.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.45.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.63 points at the first support level, and at 15.12 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.41, and for the 2nd resistance point, it is at 16.68.
Ratios To Look Out For
It is important to note that Avadel Pharmaceuticals plc [NASDAQ:AVDL] has a current ratio of 2.85. Further, the Quick Ratio stands at 2.60, while the Cash Ratio is 0.75. Considering the valuation of this stock, the price to sales ratio is 28.14, the price to book ratio is 19.77.
Transactions by insiders
Recent insider trading involved MCHUGH THOMAS S, Chief Financial Officer, that happened on Jan 16 ’24 when 2000.0 shares were purchased. Director, McCamish Mark Anthony completed a deal on Dec 28 ’23 to sell 75000.0 shares. Meanwhile, Chief Financial Officer MCHUGH THOMAS S bought 2000.0 shares on Aug 14 ’23.
